Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Among adults hospitalized with influenza, Tamiflu treatment on the day of hospital admission was associated with a reduced risk for disease progression.

Last year, a puzzling case caught the attention of Dr. Mary Lee-Wong at Maimonides Medical Center. An elderly patient with both asthma and chronic obstructive pulmonary disease had shown no signs of ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpo ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...